View in EDS HTML Full Text PDF Full Text

Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia.

Saved in:
Bibliographic Details
Title: Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia.
Authors: Bell CC; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Fennell KA; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Chan YC; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Rambow F; Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, KU Leuven, Leuven, Belgium., Yeung MM; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Vassiliadis D; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Lara L; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Yeh P; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Martelotto LG; Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia., Rogiers A; Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, KU Leuven, Leuven, Belgium.; Department of Oncology, KU Leuven, Leuven, Belgium., Kremer BE; Epigenetics DPU, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Barbash O; Epigenetics DPU, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Mohammad HP; Epigenetics DPU, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Johanson TM; The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.; The Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia., Burr ML; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Dhar A; Epigenetics DPU, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Karpinich N; Epigenetics DPU, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Tian L; The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.; The Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia., Tyler DS; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., MacPherson L; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Shi J; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA., Pinnawala N; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Yew Fong C; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Papenfuss AT; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.; The Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia., Grimmond SM; Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia., Dawson SJ; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia., Allan RS; The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.; The Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia., Kruger RG; Epigenetics DPU, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Vakoc CR; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA., Goode DL; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Naik SH; The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.; The Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia., Gilan O; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Lam EYN; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Marine JC; Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, KU Leuven, Leuven, Belgium.; Department of Oncology, KU Leuven, Leuven, Belgium., Prinjha RK; Epigenetics DPU, GlaxoSmithKline, Collegeville, Pennsylvania, USA., Dawson MA; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Mark.Dawson@petermac.org.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. Mark.Dawson@petermac.org.; Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Mark.Dawson@petermac.org.; Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia. Mark.Dawson@petermac.org.
Source: Nature communications [Nat Commun] 2019 Jun 20; Vol. 10 (1), pp. 2723. Date of Electronic Publication: 2019 Jun 20.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2041-1723
DOI:10.1038/s41467-019-10652-9